Naunyn-Schmiedeberg's Arch Pharmacol
Donato MT, Jimenez N, Castell JV, Gomez-Lechon MJ (2004)
Fluorescence-based assays for screening nine cytochrome P450
(P450) activities in intact cells expressing individual human P450
enzymes. Drug Metab Dispos 32:699–706
Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006)
Pharmacogenomics and individualized drug therapy. Annu Rev
Med 57:119–137
Fischer A, Don CG, Smieško M (2018) Molecular dynamics simulations
reveal structural differences among allelic variants of membrane-
anchored cytochrome P450 2D6. J Chem Inf Model 58:1962–1975
Fogelman SM, Schmider J, Venkatakrishnan K, Von Moltke JJ, Harmatz
JS, Shader RI, Greenblatt DJ (1999) O- and N-demethylation of
venlafaxine in vitro by human liver microsomes and by effect of
m e t a b o l i c i n h i b i t o r s a n d S S R I a n t i d e p r e s s a n t s .
Neuropsychopharmacol 20:480–490
Mo SL, Liu WF, Li CG, Zhou ZW, Luo HB, Chew H, Liang J, Zhou
SF (2012) Pharmacophore, QSAR, and binding mode studies
of substrates of human cytochrome P450 2D6 (CYP2D6) using
molecular docking and virtual mutations and an application to
chinese herbal medicine screening. Curr Pharm Biotechnol 13:
1640–1704
Modi S, Paine MJ, Sutcliffe MJ, Lian LY, Primrose WU, Wolf CR (1996)
A model for human cytochrome P450 2D6 based on homology
modeling and NMR studies of substrate binding. Biochemistry 35:
4540–4550
Niwa T, Hiroi T, Tsuzuki D, Yamamoto S, Narimatsu S, Fukuda T,
Azuma J, Funae Y (2004) Effect of genetic polymorphism on the
metabolism of endogenous neuroactive substances, progesterone
and p-tyramine, catalyzed by CYP2D6. Mol Brain Res 129:117–
123
Omura T, Sato R (1964) The carbon monoxide-binding pigment of liver
microsomes: 1. Evidence for its hemoprotein nature. J Biol Chem
239:2370–2378
Oscarson M, Hidestrand M, Johansson I, Ingelman-Sundberg M (1997)
A combination of mutation in the CYP2D6*17 (CYP2D6Z) allele
causes alterations in enzyme function. Mol Pharmacol 52:1034–
1040
Phillips AH, Langdon RG (1962) Hepatic triphosphopyridine nucloetide-
cytochrome c reductase: isolation, characterization, and kinetic stud-
ies. J Biol Chem 237:2652–2660
Pritchard MP, Glancey MJ, Blake JAR, Gilham DE, Burchell B, Wolf
CR, Friedberg T (1998) Functional co-expression of CYP2D6 and
human NADPH cytochrome P450 reductase in Escherichia coli.
Pharmacogenetics 8:33–42
Ramamoorthy Y, Tyndale RF, Sellers EM (2001) Cytochrome P450
2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for
multiple substrates. Pharmacogenetics 1:477–487
Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK,
Lewis CJ, Tennant MG, Modi S, Eggleston DS, RJBr C, idges AM
(2006) Crystal structure of human cytochrome P450 2D6. J Biol
Chem 281:7614–7622
Sakuyama K, Sasaki T, Ujiie S, Obata K, Mizugaki M, Ishikawa M,
Hiratsuka M (2008) Functional characterization of 17 CYP2D6 al-
lelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47- 51, 53-55,
and 57). Drug Metab Dispos 36:2460–2467
Senda C, Yamaura Y, Kobayashi K, Fujii H, Minami H, Sasaki Y, Igarashi
T, Chiba K (2001) Influence of the CYP2D6*10 allele on the me-
tabolism of mexiletine by human liver microsomes. Br J Clin
Pharmacol 52:100–103
Fukuda T, Nishida Y, Imaoka S, Hiroi T, Naohara M, Funae Y, Azuma J
(2000) The decrease in vivo clearance of CYP2D6 substrates by
CYP2D6*10 might be caused not only but the low expression but also
by low affinity of CYP2D6. Arch Biochem Biophys 380:303–308
Fukuyoshi S, Kometani M, Watanabe Y, Hiratsuka M, Yamaotsu N,
Hirono S, Manbe N, Takahashi O, Oda A (2016) Molecular dynam-
ics simulations to investigate the influences of amino acid mutations
on protein three-dimensional structures of cytochrome P450 2D6.1,
2, 10, 14A, 51 and 62. PLoS One 11:1–16
Ghosal A, Hapangama N, Yuan Y, Lu X, Horne D, Patrick JE, Zbaida S
(2003) Rapid determination of enzyme activities of recombinant
human cytochromes P450, human liver microsomes and hepato-
cytes. Biopharm Drug Dispos 24:375–384
Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2
(CYP2) proteins inferred from comparative analyses of amino acid
and coding nucleotide sequences. J Biol Chem 267:83–90
Handa K, Nakagome I, Yamaotsu N, Gouda H, Hirono S (2014) In silico
study on the inhibitory interaction of drugs with wild-type
CYP2D6*1 and the natural variant CYP2D6*17. Drug Metab
Pharmacokinet 29:52–60
Hevener KE, Zhao W, Ball DM, Babaoglu K, Qi J, White SW, Lee RE
(2009) Validation of molecular docking programs for virtual screening
against dihydropteroate synthase. J Chem Inf Model 49:444–460
Hu X-X, Yuan L-J, Fang P, Mao Y-H, Zhan Y-Y, Li X-Y, Dai D-P, Cai J-P,
Hu G-X (2016) Effect of CYP2D6 genetic polymorphism on the
metabolism of citalopram in vitro. Drug Metab Pharmacokinet 31:
133–138
Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome
P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects
and functional diversity. Pharmacogenomics J 5:6–13
Johansson I, Ingelman-Sundberg M (2011) Genetic polymorphism and
toxicology with emphasis on cytochrome P450. Toxicol Sci 120:1–13
Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-
Sundberg M (1994) Genetic analysis of the Chinese cytochrome
P4502D locus: characterization of variant CYP2D6 genes present
in subjects with diminished capacity for debrisoquine hydroxyl-
ation. Mol Pharmacol 46:452–459
Shen HW, He MM, Liu HF, Wrighton SA, Wang L, Guo B, Li C (2007)
Comparative metabolic capabilities and inhibitory profiles of
CYP2D6.1, CYP2D6.10 and CYP2D6.17. Drug Metab Dispos 35:
1292–1300
Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF (2009)
New insights into the structural characteristics and functional rele-
vance of the human cytochrome P450 2D6 enzyme. Drug Metab
Rev 41:573–643
Lewis DF (1995) Three-dimensional models of human and other mam-
malian microsomal P450s constructed from an alignment with
P450102 (P450bm3). Xenobiotica 25:333–366
Wang A, Savas U, Hsu MH, Stour CD, Johnson EF (2012) Crystal struc-
ture of human cytochrome P450 2D6 with prinomastat bound. J Biol
Chem 287:10834–10843
Man M, Farmen M, Dumaual C, Teng CH, Moser B, Irie S, Noh GJ, Njau
R, Close S, Wise S, Hockett R (2010) Genetic variation in metabo-
lizing enzyme and transporter genes: comprehensive assessment in 3
major East Asian subpopulations with comparison to Caucasians
and Africans. J Clin Pharmacol 50:929–940
Wennerholm A, Jahansson I, Hilderstrand M, Bertilsson L, Gustafsson
LL, Ingelman-Sundberg M (2001) Characterization of the
CYP2D6*29 allele commonly present in a black Tanzanian popula-
tion causing reduced catalytic activity. Pharmacogenetics 11:417–
427
Marcucci KA, Pearce RE, Crespi C, Steimel DT, Leeder JS, Gaedigk A
(2002) Characterization of cytochrome P450 2D6.1 (CYP2D6.1),
CYP2D6.2 and CYP2D6.17 activities towards model CYP2D6 sub-
strates dextromethorphan, bufuralol and debrisoquine. Drug Metab
Dispos 30:595–601
Yu A, Kneller BM, Rettie AE, Haining RL (2002) Expression,
purification, biochemical characterization and comparative
function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10
and 2D6.17 allelic isoforms. J Pharmacol Exp Ther 303:
1291–1300